Diuril

(chlorothiazide)

ApprovedSmall molecule

SSalix

Diuril is one of 39 small molecule programs targeting Nephrogenic Diabetes Insipidus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Nephrogenic Diabetes InsipidusActive, not recruiting

Heart FailureCompleted

Nephrogenic Diabetes InsipidusPreclinical

Active, not recruiting

Heart FailureApproved

Completed

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Diuril

SSalix

Approved

2 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure2 trials

Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance

Terminated·UUniversity of Virginia·Phase 4·NCT03574857·5 enrolled

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

Completed·VVanderbilt University·Phase 4·NCT02606253·60 enrolled

Nephrogenic Diabetes Insipidus1 trial

Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus

Completed·NNational Center for Research Resources (NCRR)··NCT00004360

Hypertension1 trial

Treatment of Hypertension

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000484

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

DIURIL

NDA NDA011145

Jan 1, 1982

DIURIL

NDA NDA011870

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for chlorothiazide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chlorothiazide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chlorothiazide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011145). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Salix company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSalix

Diuril

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure2 trials

Nephrogenic Diabetes Insipidus1 trial

Hypertension1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News